Physiological and x-ray studies of potential antisickling agents
- PMID: 6572894
- PMCID: PMC393369
- DOI: 10.1073/pnas.80.2.324
Physiological and x-ray studies of potential antisickling agents
Abstract
Several aromatic compounds have been found to inhibit the gelling of sickle cell hemoglobin. We have tried to correlate the antigelling activity of such compounds with the stereo-chemistry of their binding sites in the hemoglobin molecule. This approach led to the discovery that two known antilipoproteinemia drugs, clofibrate and gemfibrozil, have antigelling activity. X-ray analysis showed that three pairs of molecules of clofibric acid, the active metabolite of clofibrate, bound to the walls of the internal cavity of deoxyhemoglobin A; only one pair bound to a quite different site, between helices A, E, and H of the alpha chains of carbon monoxide hemoglobin A. Unlike other antigelling agents, clofibric acid and related compounds decrease rather than increase the oxygen affinity of hemoglobin.
Similar articles
-
Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.Molecules. 2016 Aug 13;21(8):1057. doi: 10.3390/molecules21081057. Molecules. 2016. PMID: 27529207 Free PMC article.
-
Design, Synthesis, and Biological Evaluation of Ester and Ether Derivatives of Antisickling Agent 5-HMF for the Treatment of Sickle Cell Disease.Mol Pharm. 2017 Oct 2;14(10):3499-3511. doi: 10.1021/acs.molpharmaceut.7b00553. Epub 2017 Sep 13. Mol Pharm. 2017. PMID: 28858508 Free PMC article.
-
Design, synthesis, and testing of antisickling agents. 2. Proline derivatives designed for the donor site.J Med Chem. 1983 Apr;26(4):549-54. doi: 10.1021/jm00358a017. J Med Chem. 1983. PMID: 6834388
-
Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.Expert Rev Hematol. 2012 Jun;5(3):303-11. doi: 10.1586/ehm.12.20. Expert Rev Hematol. 2012. PMID: 22780210 Review.
-
Pathophysiologically based drug treatment of sickle cell disease.Trends Pharmacol Sci. 2006 Apr;27(4):204-10. doi: 10.1016/j.tips.2006.02.007. Epub 2006 Mar 13. Trends Pharmacol Sci. 2006. PMID: 16530854 Review.
Cited by
-
Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.Expert Opin Ther Pat. 2022 Feb;32(2):115-130. doi: 10.1080/13543776.2022.1994945. Epub 2021 Nov 1. Expert Opin Ther Pat. 2022. PMID: 34657559 Free PMC article. Review.
-
Photoaffinity labelling of cyanomethaemoglobin with derivatives of tryptophan and 5-bromotryptophan.Biochem J. 1995 May 15;308 ( Pt 1)(Pt 1):251-60. doi: 10.1042/bj3080251. Biochem J. 1995. PMID: 7755572 Free PMC article.
-
Merging cultures and disciplines to create a drug discovery ecosystem at Virginia commonwealth university: Medicinal chemistry, structural biology, molecular and behavioral pharmacology and computational chemistry.SLAS Discov. 2023 Sep;28(6):255-269. doi: 10.1016/j.slasd.2023.02.006. Epub 2023 Feb 28. SLAS Discov. 2023. PMID: 36863508 Free PMC article. Review.
-
Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity.J Clin Invest. 1999 Mar;103(5):739-46. doi: 10.1172/JCI6030. J Clin Invest. 1999. PMID: 10074492 Free PMC article.
-
Aryloxyalkanoic Acids as Non-Covalent Modifiers of the Allosteric Properties of Hemoglobin.Molecules. 2016 Aug 13;21(8):1057. doi: 10.3390/molecules21081057. Molecules. 2016. PMID: 27529207 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources